Sheboygan Health Services Medicare and Medicaid Location: 3129 Michigan Ave, Sheboygan, Wisconsin 53082 Ratings: Phone: (920) 458-1155 |
Sheboygan Progressive Health Services Medicare and Medicaid Location: 1902 Mead Ave, Sheboygan, Wisconsin 53081 Ratings: Phone: (920) 458-8333 |
Sunny Ridge Nursing And Rehabilitation Center, Llc Medicare and Medicaid Location: 3014 Erie Ave, Sheboygan, Wisconsin 53081 Ratings: Phone: (920) 459-3028 |
Sheboygan Senior Community Inc Medicare and Medicaid Location: 3505 County Road Y, Sheboygan, Wisconsin 53083 Ratings: Phone: (920) 458-2137 |
Meadow View Health Services Medicare and Medicaid Location: 3613 S 13th St, Sheboygan, Wisconsin 53081 Ratings: Phone: (920) 458-4040 |
Morningside Health Services Medicare and Medicaid Location: 3431 N 13th St, Sheboygan, Wisconsin 53083 Ratings: Phone: (920) 457-5046 |
News Archive
Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announced at BIO2010 in Chicago that its proposal to conduct a Phase I clinical trial on SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma, has been approved in the UK by the Gene Therapy Advisory Committee and by the Medicines and Healthcare products Regulatory Agency Medicines Division.
Watson Pharmaceuticals, Inc, today announced that it has reached a settlement agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Watson's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15mg, 30mg and 45mg tablets.
Women were more likely than men to report feeling stigmatized about abdominal fat, regardless of their body mass index or weight, according to preliminary research to be presented at the American Heart Association's Scientific Sessions 2021.
In recent years, hospital charges and Medicare payments for patients with hip fractures have increased much more rapidly than charges and payments for orthopaedic surgeons, reports a study in the Journal of Orthopaedic Trauma.
ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today reported encouraging clinical data with its IMGN901 product candidate in the treatment of relapsed and relapsed/refractory multiple myeloma (MM), including prolonged benefit in patients whose disease had progressed on multiple prior treatment regimens.
› Verified 2 days ago